73 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
RDY Dr. Reddy's Laboratories Ltd $35.7 $5.93B N/A
Article Searches
Dr. Reddy's (RDY) Q4 Earnings Fall, Revenues Decline Y/Y http://www.zacks.com/stock/news/304716/dr-reddys-rdy-q4-earnings-fall-revenues-decline-y-y?cid=CS-ZC-FT-304716 May 23, 2018 - Dr. Reddy's bottom line and top line suffered a year-over-year decline, in the fourth quarter of fiscal 2018.
Dr. Reddy's Sells Antibiotic Production Hub to UAE Drugmaker http://www.zacks.com/stock/news/325877/dr-reddys-sells-antibiotic-production-hub-to-uae-drugmaker?cid=CS-ZC-FT-325877 Oct 02, 2018 - Dr. Reddy's (RDY) divests its Bristol, TN-based antibiotic manufacturing site and related assets to an Abu Dhabi-based company.
J&J Gets Positive CHMP Opinion for Prostate Cancer Treatment http://www.zacks.com/stock/news/338281/jj-gets-positive-chmp-opinion-for-prostate-cancer-treatment?cid=CS-ZC-FT-338281 Nov 19, 2018 - Johnson & Johnson's (J&J) apalutamide gets positive CHMP opinion for the treatment of adult patients with non-metastatic castration-resistant prostate cancer.
Generic Industry on Path to Recovery: 3 Hot Picks for 2019 http://www.zacks.com/stock/news/345019/generic-industry-on-path-to-recovery-3-hot-picks-for-2019?cid=CS-ZC-FT-345019 Dec 28, 2018 - The stability in the industry sets the stage for players to get back on growth track. Here we discuss three stocks picks from the industry.
Teva (TEVA) Ends Dispute with Amgen Over Generic Sensipar http://www.zacks.com/stock/news/345603/teva-teva-ends-dispute-with-amgen-over-generic-sensipar?cid=CS-ZC-FT-345603 Jan 03, 2019 - Teva (TEVA) ends an ongoing patent dispute with Amgen over generic Sensipar by making an undisclosed payment.
Akorn (AKRX) Gets FDA Warning Letter for Illinois Facility http://www.zacks.com/stock/news/346828/akorn-akrx-gets-fda-warning-letter-for-illinois-facility?cid=CS-ZC-FT-346828 Jan 10, 2019 - Akorn, Inc. (AKRX) suffers a setback with the FDA handing over a warning letter post an inspection of its Illinois manufacturing facility in April and May of 2018.
Falling Earnings Estimates Signal Weakness Ahead for Mylan (MYL) http://www.zacks.com/stock/news/365966/falling-earnings-estimates-signal-weakness-ahead-for-mylan-myl?cid=CS-ZC-FT-365966 Mar 28, 2019 - Mylan (MYL) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
Dr. Reddy's (RDY) Earnings Rise in Q4, Revenues Beat http://www.zacks.com/stock/news/415513/dr-reddys-rdy-earnings-rise-in-q4-revenues-beat?cid=CS-ZC-FT-415513 May 17, 2019 - Dr. Reddy's earnings and sales increase year over year in the fourth quarter of fiscal 2019.
New Strong Sell Stocks for May 22nd http://www.zacks.com/stock/news/417826/new-strong-sell-stocks-for-may-22nd?cid=CS-ZC-FT-417826 May 22, 2019 - Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Dr. Reddy's Reports Positive Top-Line Data on Psoriasis Drug http://www.zacks.com/stock/news/427399/dr-reddys-reports-positive-top-line-data-on-psoriasis-drug?cid=CS-ZC-FT-427399 Jun 10, 2019 - Dr. Reddy's (RDY) reports positive top-line results from the phase IIb study on PPC-06 (formerly referred to as XP23829) in patients with moderate to severe plaque psoriasis.

Pages: 12345678

<<<Page 7